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Targeted detection of genetic alterations
reveal the prognostic impact of H3K27M
and MAPK pathway aberrations in
paediatric thalamic glioma
Scott Ryall1,2 , Rahul Krishnatry1,3, Anthony Arnoldo4, Pawel Buczkowicz1,4, Matthew Mistry1, Robert Siddaway1,
Cino Ling1, Sanja Pajovic1, Man Yu1, Joshua B. Rubin5, Juliette Hukin6, Paul Steinbok7, Ute Bartels3, Eric Bouffet3,
Uri Tabori1,3,8 and Cynthia Hawkins1,2,4,9*
Abstract
Paediatric brain tumours arising in the thalamus present significant diagnostic and therapeutic challenges to physicians
due to their sensitive midline location. As such, genetic analysis for biomarkers to aid in the diagnosis, prognosis and
treatment of these tumours is needed. Here, we identified 64 thalamic gliomas with clinical follow-up and characterized
targeted genomic alterations using newly optimized droplet digital and NanoString-based assays. The median age at
diagnosis was 9.25 years (range, 0.63–17.55) and median survival was 6.43 (range, 0.01–27.63) years. Our cohort
contained 42 and 22 tumours reviewed as low and high grade gliomas, respectively. Five (12 %) low grade and 11
(50 %) high grade gliomas were positive for the H3F3A/HIST1H3B K27M (H3K27M) mutation. Kaplan-Meier survival
analysis revealed significantly worse overall survival for patients harbouring the H3K27M mutation versus H3F3A/
HIST1H3B wild type (H3WT) samples (log-rank p < 0.0001) with a median survival of 1.02 vs. 9.12 years. Mitogen-activated
protein kinase (MAPK) pathway activation via BRAF or FGFR1 hotspot mutations or fusion events were detected in 44 %
of patients, and was associated with long-term survival in the absence of H3K27M (log-rank p < 0.0001). Multivariate
analysis demonstrated H3K27M status and high grade histology to be the most significant independent predictors of
poor overall survival with hazard ratios of 6.945 and 7.721 (p < 0.0001), respectively. In contrast, MAPK pathway activation
is a predictor of favourable patient outcome, although not independent of other clinical factors. Importantly, we show
that low grade malignancies may harbour H3K27M mutations and that these tumours show a dismal survival compared
to low grade H3WT cases. Our data strongly supports the inclusion of targeted genetic testing in childhood thalamic
tumours to most accurately stratify patients into appropriate risk groups.
Keywords: Thalamic glioma, Pediatric, H3K27M, MAPK, BRAF, Prognostic
Introduction
Brain tumours are the largest group of solid tumours
and the leading cause of tumour-related death in chil-
dren [4]. In particular, tumours arising in midline
structures of the brain including the brainstem and
thalamus present significant challenges for physicians
in regards to their therapeutic approach. At present,
tumours arising in the brainstem, known as diffuse
intrinsic pontine glioma (DIPG), have been extensively
investigated and stratified into disease subtypes [6, 20].
Whereas DIPG is heavily researched, thalamic tu-
mours, accounting for approximately 5 % of all paedi-
atric brain neoplasms, are largely unexplored [8–10,
14, 27, 28]. Currently, the outcome of patients with
thalamic tumours is predicted based on the histo-
logical grade and the potential for surgical resection
of the tumour. High grade tumours classified as
World Health Organization (WHO) grade III or IV
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are associated with worse clinical outcome as com-
pared to grade I or II low grade tumours [23, 24].
Due to their precarious midline location and the vital
functions of the thalamus and nearby structures, these
tumours, particularly the diffuse gliomas, often cannot
be completely resected, which is associated with a
worse clinical outcome [2, 10, 22, 27]. Further, limited
resections also potentially lead to sampling related er-
rors in histological grading due to small biopsy speci-
mens [12, 26]. As such, there is a need to identify
genetic biomarkers to supplement histological grading
and extent of surgical resection to aid in the diagno-
sis and management of thalamic tumour cases.
Recent studies have identified several biomarkers
that aid in disease diagnosis and are important in
predicting patient outcome in childhood gliomas. Re-
current mutations in histone H3 in which lysine 27
is substituted for methionine (H3K27M) were first
described in patients with paediatric high grade gli-
oma, primarily DIPG [20, 31, 33]. When correlated
to clinical outcome, the presence of H3K27M in
DIPG was associated with worse overall survival as
compared to those with wild type H3 (H3WT) sta-
tus, regardless of the histology of the tumour [5, 20,
21]. Subsequent studies have identified H3K27M mu-
tations in other high grade midline tumours, includ-
ing those in the thalamus, but have not looked
directly at its impact on patient survival [5, 31, 33].
In addition to H3K27M, genetic aberrations affecting
the RAS-MAPK pathway including KIAA1549-BRAF
and other BRAF, RAF and FGFR fusion events, as
well as BRAF and FGFR1 point mutations have been
described primarily in hemispheric low grade gliomas
in adults and children [7, 18, 19, 30, 34]. KIAA1549-
BRAF fusions have previously been shown to be as-
sociated with better patient survival [3, 15] while
BRAFV600E has been linked to increased likelihood
of tumour progression and transformation in low
grade glioma [17, 25]. FGFR1 aberrations including
N546K and fusion events with TACC were reported
in low grade paediatric astrocytomas [18, 34] and
the former shown to be a negative prognostic
marker in a small cohort of grade I pilocytic astrocy-
tomas [3]. However, thalamic gliomas are often
under-represented in glioma cohorts because their
midline location often means only a biopsy is per-
formed and there is little tissue available to study.
Thus a comprehensive study of genetic markers and
their role relative to histologic and clinical risk fac-
tors has not been performed for thalamic glioma. To
address this limitation, we assembled a cohort of
concisely defined paediatric thalamic glioma. We in-
vestigated the diagnostic and prognostic roles of de-
fined genetic, clinical and histologic markers.
Materials and methods
Patient cohort
After institutional ethics board approval of the study, re-
view of the pathology and oncology databases at the To-
ronto Hospital for Sick Children (SickKids) identified
101 patients diagnosed with thalamic glioma in the MRI
era (1986 to 2014). As SickKids is the only reference
center for children in a population of 5 million people,
no selection bias is expected, and this qualifies as a
population-based study. All cases were centrally
reviewed for pathological diagnosis and grading accord-
ing to WHO criteria (CH) [23]. Where available, MRIs
were reviewed to confirm thalamic tumour origin (RK).
Twenty-three tumours originally identified as thalamic
were determined to not be central to or originating from
the thalamus but rather, involved the thalamus and were
excluded. Four cases were excluded due to bi-thalamic
involvement. Ten tumours were excluded due to insuffi-
cient material yielding a final cohort of 64 (Additional
file 1: Table S1). We further assembled an independent
trans-Canadian cohort as previously described [32]
which was used for validation purposes (Additional file 2:
Table S2).
DNA/RNA isolation
DNA was extracted from 5 to 10 10 μm thick scrolls of
formalin-fixed-paraffin-embedded (FFPE) tissue using
the MasterPure Complete DNA and RNA Purification
Kit (Epicentre, WI, USA) according to the manufac-
turer’s instructions with a modified proteinase K diges-
tion in which incubation time was increased from 24 to
48 h. Total RNA was extracted from FFPE tissue with
the RNeasy FFPE extraction kit (QIAGEN, CA, USA)
using the manufacturer’s guidelines. RNA/DNA quality
was assessed based on 260/280 values obtained using
the NanoDrop 2000 (Thermo Scientific, DE, USA) and
samples between 1.7–1.9 and 1.9–2.0 were considered to
be of sufficient quality for DNA and RNA, respectively.
Samples were quantified using the Qubit Fluorometer
V2.0 (Thermo Scientific, DE, USA).
ddPCR mutation detection
The Bio-Rad (Hercules, CA, USA) QX200 ddPCR sys-
tem was used to detect H3K27M (including H3F3A and
HIST1H3B/C due to sequence similarity), H3F3A-
G34V/R, BRAFV600E and FGFR1N546K mutations.
Droplet digital PCR (ddPCR) workflow was completed
as described [16]. Samples temporarily consisted of 1X
ddPCR Supermix for Probes (no dUTP) (Bio-Rad),
900nM of specific forward and reverse primers, 250nM
of specific mutant and wild type specific probe, and 10–
50 ng of genomic DNA depending on the quality. Each
reaction was mixed with 70 μl of Droplet Generation Oil
(Bio-Rad) and partitioned into a minimum of 10,000
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droplets, transferred to a 96-well plate and sealed prior
to PCR amplification. PCR amplification was completed
in a C1000 thermo cycler (Bio-Rad) with the following
cycling conditions: 1 x (95 °C for 10 min), 39 x (95 °C
for 30 s, 55 °C for 60 s, with 2 °C s-1 ramp rate), and 1 x
(98 °C for 10 min). Following amplification, fluorescent
intensity was measured with the QX200 Droplet Reader
(Bio-Rad) and data analysis performed with the Quanta-
Soft droplet reader software (Bio-Rad). All samples were
run in duplicate to ensure validity. Samples were consid-
ered positive if a minimum of 10 mutant droplet and
1 % mutant allele frequency were detected in both dupli-
cate runs. This threshold was arbitrarily set and we re-
port no false positive detection ever approaching this
defined threshold.
The ddPCR assay was fully optimized for clinical im-
plementation. DNA loading concentration, PCR settings,
and reaction conditions were corrected to ensure suffi-
cient probe separation for confident mutation identifica-
tion (Additional file 3: Figure S1, Additional file 4:
Figure S2, and Additional file 5: Figure S3). A cohort of
clinical DIPG and high grade astrocytoma samples previ-
ously evaluated with whole exome sequencing (WES)
(Applied Biosystems SOLiD 5500xl) were used to com-
pare methods [20]. ddPCR showed 100 % concordance
with WES calls from both fresh frozen and FFPE sam-
ples (Additional file 6: Table S3 and Additional file 7:
Table S4). Importantly, it must be noted that due to se-
quence similarity, the H3K27M droplet digital probe is
unable to distinguish between H3F3A and HIST1H3B/
C, and hence will detect a K27M mutation in any of the
aforementioned genes. Similar optimization procedures
were completed for H3G34V/R, BRAFV600E and
FGFR1N546K (data not shown). Assay sensitivity was
determined by serially diluting an H3K27M-positive
sample with normal DNA from 50 to 0.01 % MAF
(Additional file 8: Figure S4). The ddPCR assay was able
to accurately detect the mutation at allele frequencies as
low as 1 % in FFPE preserved samples in accordance with
the minimum detection limits described above.
NanoString fusion detection
Probes targeting the 33 most commonly reported fusions
in paediatric glioma (Additional file 9: Table S5) were
designed in collaboration with NanoString (WA, USA).
Five hundred nanograms of total RNA was added to the
nCounter Elements TagSet in hybridization buffer and
incubated at 67 °C for 20 h. The sample was processed
on the nCounter Preparation Station and the cartridge
scanned at 555 fields of view on the nCounter Digital
Analyzer. Raw counts were subjected to a technical
normalization using counts obtained for positive control
probe sets included in each run. The statistical outlier
detection method was used to detect the presence of an
expressed fusion. Data is viewed using a box plot and
the presence of an extreme outlier (3xIQR) indicate fu-
sion expression.
Statistics
Statistical analysis was performed using SPSS v23 (IBM
Corporation) or GraphPad Prism 5 (La Jolla, CA, USA).
Overall survival was determined using the Kaplan–Meier
method and univariate assessments of Kaplan–Meier
plots were tested using log rank. p values <0.05 were
considered to be statistically significant. Multivariate
Cox proportional hazard models and significance based
on the Wald test (α = 0.05) were performed for multi-
variate analysis.
Results
Clinical characteristics of patients with thalamic glioma
Sixty-four patients treated at the Hospital for Sick
Children from 1986 to 2014 were identified as thalamic
tumour patients. Forty-two thalamic tumours were his-
tologically diagnosed as low grade glioma (62 % grade I,
5 % grade II, and 33 % low grade glioma, NOS) whereas
the remaining 22 were diagnosed as high grade glioma
(41 % grade III, 50 % grade IV, and 9 % high grade,
NOS). Two (5 %) low grade gliomas later transformed to
high grade malignancies. Median age of diagnosis for
thalamic glioma patients was 9.25 years (range, 0.63–
17.55 years). Forty-one (64 %) patients received surgical
resection (5 partial, 25 subtotal and 11 gross total resec-
tion) while 23 (36 %) were biopsied only. Thirty-five
(55 %) and 37 (58 %) patients were treated with chemo-
therapy and/or radiation, respectively. Thirty-five (55 %)
patients are alive (median follow-up, 12.2 years) while 29
(45 %) patients succumbed to their disease. A summary
of the clinical characteristics are shown in Table 1. Clin-
ical characteristics of the Canadian cohort reflect those
described above and are available in Additional file 10:
Table S6.
Landscape of point mutations and fusion events in
thalamic tumours
ddPCR and NanoString assays were used to identify tar-
geted mutations and fusions of interest based on their
previous association with paediatric glioma (Fig. 1). The
most recurrent hotspot mutation was H3K27M, identi-
fied in 16 (25 %) thalamic tumours tested. No H3G34R/
V mutations were observed as expected. BRAFV600E
mutations were present in 10 (16 %) cases, with 2 co-
occurring with H3K27M mutations. KIAA1549-BRAF
fusion events including those involving exons 16;09,
16;11 and 15;09 in order of prevalence, were detected in
14 (39 %) of the 36 samples from which sufficient quality
RNA was obtained. These were mutually exclusive with
H3K27M, BRAFV600E and FGFR fusions/mutations.
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FGFR1N546K mutations were seen in 4 (6 %) tumour
samples. No FGFR1-TACC1, FGFR3-TACC3, other
BRAF or RAF fusions or MYBL1 alterations were de-
tected in this cohort. Within the Canadian cohort,
H3K27M was identified in 5 (31 % of patients),
BRAFV600E in 3 (19 %) and KIAA1549-BRAF fusion
events in 3 (20 %) of 15 patients tested. No
FGFR1N546K or FGFR1-TACC1, FGFR3-TACC3, other
BRAF or RAF fusions or MYBL1 alterations were de-
tected within this cohort. Genetic aberration frequencies
based on histological grade can be seen in Additional
file 11: Table S7.
High grade histology and H3K27M are markers of poor
prognosis in thalamic glioma
Tumours diagnosed as high grade glioma (grades III and
IV) showed significantly worse overall survival when
compared to those defined as low grade (grade I and II)
in both the SickKids and Canadian cohorts (Additional
file 12: Figure S5). This trend was conserved with the re-
moval of PA and GG from the low grade histology co-
hort (log-rank p = 0.0027). 5+ year overall survival for
patients diagnosed with a high grade glioma was 9.1 %
(2/22) as compared to 76.2 % (32/42) in tumours with
low grade histology. 9.1 % and 78.6 % of high and low
grade patients respectively were alive at the time the
study was completed. Likewise, the presence of
H3K27M was significantly related to worse patient out-
come (Fig. 2a, log-rank p < 0.0001). Patients harbouring
the H3K27M mutation had a 5+ year overall survival of
6.3 % (1/16) as compared to 68.8 % (33/48) for H3WT
patients (Table 2). Similar results were observed in the
Canadian cohort (Fig. 2b, log-rank p = 0.0002). Of the 16
H3K27M positive cases, 5 and 11 were low and high
grade glioma, respectively. All 16 of these patients suc-
cumbed to their disease. No patient with a morphologic-
ally classic pilocytic astrocytoma harboured an H3K27M
mutation, suggestive of a minimum grade II histology in
NOS cases.
H3K27M is present in low grade thalamic glioma and
confers a negative prognosis
When separated based on histological grade, both
H3K27M and H3WT high grade glioma cases showed poor
prognosis (Fig. 2c), with tumours harbouring H3K27M hav-
ing slightly worse outcome (log-rank p = 0.0109). Long
term survival (5+ years) in high grade cases was exclusively
seen in H3WT patients. Strikingly, H3K27M positive low
grade cases had significantly worse outcome than H3WT
low grade tumours (log-rank p < 0.0001), with all H3K27M
patients succumbing to their disease (Fig. 2d). Upon re-
moval of PA and GG from the low grade cohort, the pres-
ence of H3K27M remained a predictor of a worse patient
outcome (log-rank p =0.0195). Interestingly, when
compared to high grade H3K27M glioma patients, pa-
tient survival was significantly longer for patients with
low grade glioma histology (median survival 1.44
[range, 0.52–13.66] and 0.76 [range, 0.12–1.52] years
for low grade versus high grade respectively, log-rank
p = 0.0361) suggesting that under-grading due to sam-
pling error does not account for the finding of
Table 1 Clinical characteristics of paediatric thalamic glioma
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H3K27M in low grade glioma. MRI review of available
cases showed no obvious differences within the low grade
H3K27M cases to suggest that a high grade tumour was
present. Importantly, of patients with low grade thalamic
gliomas and H3WT genotype, 89 % were alive at the com-
pletion of this study (median follow-up 12.2 years). Four
low grade H3WT cases succumbed to their disease, all of
which were WT for all aberrations tested in this study.
Taken together, the presence of low grade histology and
H3WT status resulted in the most favourable patient out-
come, while high grade histology and H3K27M resulted in
the worst outcome (Fig. 2e). Low grade histology in the
presence of H3K27M as well as high grade H3WT cases
act intermediately. Similar clinical outcome in H3K27M
and H3WT cases were observed within the Canadian co-
hort (Additional file 13: Table S8).
MAPK pathway activation is a marker of good prognosis
in thalamic glioma
MAPK pathway activation via BRAF and FGFR1 hotspot
mutations or fusion events was detected in 28 (44 %) of
childhood thalamic gliomas. BRAFV600E was detected
in 2 and 8 high and low grade gliomas, respectively. Of
the 2 high grade patients with BRAFV600E, one patient
also harboured H3K27M and had poor survival
(1.43 years) in line with the H3K27M phenotype. Anec-
dotally, the patient with H3WT high grade glioma and
BRAFV600E is still alive and has a longer survival com-
pared to most other high grade tumours (3.75 years
follow-up). In low grade gliomas, the presence of
BRAFV600E was associated with excellent overall sur-
vival (10.27 [range, 1.27–24.95] year median survival);
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Fig. 2 H3K27M is a negative prognostic marker in paediatric thalamic glioma. SickKids cohort (a) and )(b) Canadian cohort were tested for
association between H3K27M-status and survival. Sample stratification based on histological grade showed H3K27M a significant prognostic
marker in high grade (c) and low grade (d). Histology and H3K27M status combined (e) revealed clinical disease stratification
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also H3K27M-positive as compared to 100 % 5-year sur-
vival of all other cases (Fig. 3a). BRAF fusion events were
exclusively seen in low grade tumours, were never asso-
ciated with H3K27M and were associated with excellent
long-term survival (5+ year survival of 78.6 % [11/14])
(Fig. 3b). All patients harbouring a BRAF fusion event
were alive upon completion of this study (mean follow-
up 13.02 years). FGFR1 mutations were found in 6 % of
thalamic gliomas (5 % and 9 % of low and high grade tu-
mours respectively). FGFR1 mutations were observed to
co-occur with H3K27M in two cases and as with
BRAFV600E, the H3K27M phenotype of poor survival
was observed. The FGFR1 positive, H3K27M negative
patients behaved in accordance to their histological
grade, with the grade IV case succumbing to the disease
in 1.71 years while the grade I surviving 25.46 years at
the time of last follow-up. FGFR1 mutations were mutu-
ally exclusive with BRAFV600E and BRAF fusion events
in this series. Overall, the presence of MAPK pathway
activation in the absence of H3K27M was related to ro-
bust patient survival (91 % 5-year survival), whereas in
the presence of H3K27M the prognosis remained poor
across all histological grades (Fig. 3c).
H3K27M status, extent of resection and histological grade
are independent predictors of patient survival in thalamic
glioma
To determine their relative predictive values, we per-
formed univariate analysis of H3K27M, MAPK path-
way activation, extent of surgical resection, adjuvant
therapy and histological grade. On univariate analysis
histological grade (high grade versus low grade, HR
9.905 [range 4.378–22.408], p < 0.0001), extent of re-
section (resection versus biopsy, HR 0.399 [range
0.191–0.831], p = 0.014) and H3K27M status (K27M
versus WT, HR 9.403 [range 4.253–20.788], p < 0.001)
and MAPK pathway activation (Activated versus WT,
HR 0.190 [range 0.072–0.500], p = 0.001 are predictive
markers of overall survival (Table 3). On multivariate
analysis, only H3K27M status (HR 6.945, p < 0.0001),
histologic grade (HR 7.721, p < 0.0001) and extent of
surgical resection (HR 0.325, p = 0.025) were signifi-
cant independent predictors of patient survival.
Discussion
Thalamic tumours present a significant challenge for cli-
nicians in terms of accurate diagnosis and an appropri-
ate therapeutic approach. This study investigated the
prognostic potential of molecular alterations and clinical
factors in a concisely defined thalamic glioma cohort.
As expected, our results show the presence of
H3K27M mutations in 50 % of high grade paediatric
thalamic tumours [5, 20, 31, 33]. Interestingly, 12 % of
patients diagnosed with low grade thalamic tumours also
tested positive for H3K27M despite previous reports
suggesting it to be exclusive to high grade cases when
not located in the brainstem [31, 33]. Of note, two of
five low grade cases positive for H3K27M later
Table 2 Clinical characteristics of H3K27M and H3WT paediatric
thalamic glioma
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transformed to high grade malignancies at the time of
second surgery, a rare occurrence in paediatric low
grade glioma and consistent with the diagnosis of sec-
ondary HGG [25]. While it is possible that these
H3K27M positive thalamic gliomas were under-graded
histologically based on sampling bias, the significant sur-
vival difference observed between low grade and high
grade H3K27M tumours supports the idea that these tu-
mours were indeed distinct from their high grade coun-
terparts. Further, there is a lack of any distinguishing
MRI characteristics to suggest under-grading in these
cases. Importantly, under the new World Health
Organization classifications published recently, these
tumours would be classified as diffuse midline glioma,
H3-K27M mutant, further supporting their unique
identity as compared to non-H3K27M low grade tu-
mours [24].
Patients harbouring H3K27M showed significantly
worse overall survival when compared to H3WT cases.
Once separated based on histological grade, both low
and high grade tumours maintained a significantly worse
survival in the presence of H3K27M. Of note, high grade
thalamic tumours, regardless of H3K27M status, yielded
dismal survival with those harbouring the mutation suc-
cumbing to their disease in a slightly faster timeframe.
























B R A F V 6 0 0 E
B R A F V 6 0 0 E + H 3 K 2 7 M
W ild T y p e
H 3 K 2 7 M

















W i ld T y p e
B R A F F u s io n

















M A P K A c t iv a t io n
M A P K A c t iv a t io n + H 3 K 2 7 M
H 3 K 2 7 M
W ild T y p e
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Table 3 Univariate and multivariate Cox analysis of genetic and clinical determinants of paediatric thalamic glioma
Variable Univariate (95 % CI) p value Multivariate (95 % CI) p value
Histology (HG vs. LG) 9.905 [4.378–22.408] <0.0001 7.721 [2.437–24.461] <0.0001
Surgery (resection vs. biopsy) 0.399 [0.191–0.831] 0.014 0.325 [0.122–0.869] 0.025
Chemo. (yes vs. no) 0.969 [0.441–2.127] 0.969 0.549 [0.213–1.416] 0.215
Rad. (yes vs. no) 1.048 [0.459–2.396] 0.911 0.898 [0.343–2.349] 0.827
H3K27M (mut. vs. WT) 9.403 [4.253–20.788] <0.0001 6.945 [2.190–22.020] <0.0001
MAPK Activation (mut. vs. WT) 0.190 [0.072–0.500] 0.001 0.385 [0.134–1.102] 0.075
LG low grade, HG high grade
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[5, 20], where we found H3K27M to be a negative prog-
nostic marker in DIPG, albeit independent of tumour
histology. Previous research investigating the impact of
H3K27M on high grade adult midline tumours found a
correlation between H3K27M and poor survival in the
brainstem, but not the thalamus [1, 13]. Similar to this
study, in our cohort high grade histology was associated
with a poor outcome in both H3K27M and H3WT pa-
tients. However, in our cohort, several longer term survi-
vors with H3WT high grade gliomas were present
making the overall survival slightly better for H3WT
patients. Work investigating paediatric glioblastoma
(Grade IV) identified H3K27M positive cases as
showing poor survival in midline cases including
those in the brainstem and thalamic regions, consist-
ent with our findings [21].
The presence and effect of H3K27M mutations in low
grade malignancies on patient outcome has not previ-
ously been shown in malignancies outside the brainstem.
In this study, patients with low grade thalamic gliomas
had good overall survival with 79 % of patients alive
upon the completion of this study (mean follow-up
14.03 years), consistent with previous studies [3, 11, 15,
29, 30]. However, all 5 patients whose low grade gliomas
were positive for H3K27M succumbed to their disease,
with increased latency compared to high grade H3K27M
cases. These findings substantiate the knowledge that
H3K27M mutations do exist in low grade tumours and
that H3K27M status can supplement histological grading
in determining the clinical progression of the tumour.
Importantly, the poor survival of patients with H3K27M
low grade glioma suggests that they should be treated as
high grade glioma; receiving more aggressive adjuvant
therapies than would be typically given to low grade gli-
oma patients.
MAPK pathway activation was detected in 44 % of pa-
tients. BRAFV600E was detected in 10 (16 %) of the
thalamic tumour samples, a slightly lower percentage
than previously reported [29, 30]. However, in these re-
ports, the thalamus was grouped with all diencephalon-
based structures, potentially altering the true prevalence.
Furthermore, this study identified the presence of
BRAFV600E mutations in 3 grade I malignancies for the
first time, in contrast with previous reports [11]. In the
absence of H3K27M, BRAFV600E cases were associated
with a good clinical outcome. Previously we reported
that low grade tumours having BRAFV600E were at a
higher risk for developing secondary high grade glioma
[25]. However, only 3 patients within this initial study
were identified as thalamic, of which one co-occurred
with H3K27M and another with CDKN2A deletion, po-
tentially predisposing to tumour transformation. Fur-
thermore, although the results here suggest robust
survival in our BRAFV600E cohort, our median follow-
up was 10.27 years and it is possible that with longer la-
tency these patients may develop high grade glioma.
Therefore, patients harboring low grade BRAFV600E tu-
mours should be monitored closely post-treatment for
disease progression. In the presence of H3K27M,
BRAFV600E patients had an outcome similar to
BRAFWT, H3K27M-positive cases, suggesting that
H3K27M is the dominant prognostic indicator.
KIAA1549-BRAF fusion events were exclusive to low
grade thalamic glioma and were found in 39 % of tested
tumours. This percentage is similar to previous reports
in midline paediatric low grade glioma [11, 15]. How-
ever, it should be noted that these studies included non-
thalamic locations, including the cerebellum, hypothal-
amus, optic pathway and brainstem. Patients with a
KIAA1549-BRAF fusion showed robust survival, with all
14 patients alive at the time this study was completed
(median follow-up: 11.55 years). FGFR1N546K was de-
tected in 4 patients (6 %) and was seen in both low and
high grade cases. FGFR1N546K mutations have been
previously linked to decreased patient survival [3]. The
small number of patients harbouring this mutation in
this cohort means conclusions related to its prognostic
significance cannot be drawn. However, of the 4 FGFR1
mutated patients, the 2 also harbouring H3K27M
showed poor survival in accordance with the H3K27M
phenotype. Alternately, FGFR1 mutated patients without
H3K27M behaved in accordance with their histological
grade, suggesting that histology and H3K27M status are
the main phenotypic contributors in these cases. We did
not identify FGFR1-TACC1 or FGFR3-TACC3 fusions in
our cohort as described in [34].
The presence of MAPK pathway activation was found
in 28 patients within our cohort, 89 % of which were
low grade glioma. Importantly, of the 3 high grade cases
with MAPK activation, 2 were also H3K27M and be-
haved in accordance with the H3K27M phenotype. The
remaining high grade, MAPK activated sample shows a
prolonged survival in comparison to other high grade
tumours (3.75 years) and was alive upon the completion
of this study. In low grade tumours, the presence of
MAPK activation, regardless of fusion or hotspot muta-
tion event was related to prolonged survival. Taken to-
gether, H3K27M and MAPK pathway activation
effectively stratifies thalamic tumours into survival
groups. MAPK pathway activation in the absence of
H3K27M confers long-term survival across the entire
cohort irrespective of tumour histology. Tumours wild
type for the genetic targets tested here behave in close
accordance with their histological grade. Further testing
is required to identify additional genetic marks capable
of further stratifying this group. Importantly, it must be
recognized that a limitation of this study in respect to
MAPK activation is the inclusion of pilocytic
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astrocytoma and ganglioglioma within the low grade
histology category. This saturation of circumscribed and
non-invasive lesions positive for MAPK activation may
partially explain the robust survival seen. However, in
the case of thalamic tumours, the finding appear consist-
ent across histological grades and as such, remain an im-
portant clinical predictor of patient outcome. Lastly,
tumours harbouring H3K27M, regardless of histology or
MAPK activation show dismal survival. In this respect,
H3K27M is one of the most critical factors in predicting
patient outcome in thalamic glioma cases and must be
considered equally important as tumour histology in pri-
mary prognostic categorization.
Conclusions
In summary, this study supports the inclusion of tar-
geted H3K27M and MAPK activation testing via clinic-
ally approved methodology in all paediatric midline
tumours regardless of histological grade. This helps pro-
vide an accurate prediction of patient outcome and ap-
propriate therapeutic options. Further, we provide fully
optimized and cost-effective strategies to targeting these
aberrations in a clinical setting.
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